The Peroxisome Proliferator Activated Receptor Gamma pipeline drugs market research report outlays comprehensive information on the Peroxisome Proliferator Activated Receptor Gamma targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Peroxisome Proliferator Activated Receptor Gamma pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Metabolic Disorders, Gastrointestinal, Central Nervous System, and Oncology which include the indications Type 2 Diabetes, Diabetes, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alzheimer’s Disease, Parkinson’s Disease, Breast Cancer, and Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). It also reviews key players involved in Peroxisome Proliferator Activated Receptor Gamma targeted therapeutics development with respective active and dormant or discontinued products.
The Peroxisome Proliferator Activated Receptor Gamma pipeline targets constitutes close to 43 molecules. Out of which, approximately 27 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 1, 4, 5, 3, 1, 10, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 12, and 4 molecule.
Peroxisome Proliferator Activated Receptor Gamma overview
Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. It is a key regulator of adipocyte differentiation and glucose homeostasis.
For a complete picture of Peroxisome Proliferator Activated Receptor Gamma’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
